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Background. Associations between hematocrit values and
clinical outcome have been studied with conflicting results in
cardiac patients, end-stage renal disease (ESRD) patients, and
ESRD patients with cardiac disease. We studied dialysis patients
to determine the relationship between hematocrit value and
cardiac risk under current Dialysis Outcomes Quality Initiative
(DOQI) practices.
Methods. Medicare data were used to study 50,579 incident
hemodialysis patients selected from January 1, 1998, to Decem-
ber 31, 1999, who received hemodialysis for 9 months after the
onset of ESRD. Patients were divided into groups on the basis of
the hematocrit value: ≤30%, >30% to ≤33%, >33% to ≤36%,
>36% to ≤39%, and >39%. For hospitalization, the follow-up
extended to 21/2 years; for mortality, 3 years.
Results. Compared to patients with hematocrit values of
>33% to ≤36%, patients with values of >36% to ≤39% and
those with values of >39% had risk ratios for hospitalization
due to cardiac disease of 0.92 (95% CI 0.88 to 0.97) and 0.79
(95% CI 0.72 to 0.87), respectively, and risk ratios for death due
to cardiac disease of 0.92 (95% CI 0.87 to 0.98) and 0.83 (95%
CI 0.74 to 0.93), respectively, in the follow-up period.
Conclusion. The significant associations we report do not
establish a causal relationship between higher hematocrit val-
ues and lower risks of cardiac morbidity and mortality. A ran-
domized clinical trial in low-risk patients is needed to establish
causality.
Cardiovascular disease is the major cause of death in
patients with end-stage renal disease (ESRD). In patients
who were ≥67 years old and progressed to ESRD in 1997,
63% had atherosclerotic heart disease, 66% had conges-
tive heart failure (CHF), 50% had peripheral vascular
disease, 37% had cerebrovascular accidents or transient
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ischemic attacks, and 70% had other cardiac diseases [1].
For 1997 to 1999 prevalent ESRD patients, the unad-
justed death rate was 179.3 per 1000 patient-years at risk,
while the death rate due to cardiac disease was 86.9 per
1000 patient-years at risk [1].
Several investigators have reported that anemia is asso-
ciated with heart failure and left ventricular dysfunction
and that the correction of anemia in longitudinal stud-
ies was associated with reduced complication rates for
patients with these diseases [2–4]. Associations between
hematocrit values and cardiac risk, morbidity, and mor-
tality have been studied with conflicting results in cardiac
patients, ESRD patients, and ESRD patients with cardiac
disease [5–17].
Randomized clinical trials have shown the effects of
normalizing the hematocrit value in ESRD patients who
are receiving hemodialysis and have CHF and ischemic
heart disease. Besarab et al [15] found that patients
randomized to the higher hematocrit group (hematocrit
value of 42%) had a nearly statistically significant in-
creased risk of death, compared to the lower hematocrit
group (hematocrit value of 30%). Others have shown that
correction of anemia or maintenance of a normal hemat-
ocrit value in ESRD patients is not associated with worse
outcomes such as increased blood pressure [16–18].
Our previous studies found an association between
higher hematocrit values (30% to <33% or 33% to
<36%) and lower risks of hospitalization and death in
the follow-up period [19–22]. Our studies also found bet-
ter outcomes in terms of morbidity and mortality for
patients who maintained or increased hematocrit values
to 30% to 33% in a 1-year follow-up period [23] [ab-
stract; Collins AJ, et al, J Am Soc Nephrol 9:A1043, 1998;
abstract; Collins AJ, et al, J Am Soc Nephrol 9:A1044,
1998]. However, little information is available to resolve
issues in this area under current guidelines for therapy
such as the National Kidney Foundation’s Dialysis Out-
comes Quality Initiative (NKF DOQI). Therefore, we
studied a large sample of Medicare hemodialysis patients
to determine the relationship between specific cardiac
risk and hematocrit value under current DOQI practices.
Specifically, we assessed the association between elevated
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hematocrit values (>36% to ≤39% and >39%) and mor-
bidity and mortality due to cardiovascular disease, includ-
ing CHF, ischemic heart disease, cerebrovascular disease,
and other cardiac diseases in a large incident hemodialy-
sis population.
METHODS
Study design and patient population
We retrospectively studied Medicare incident
hemodialysis patients selected from January 1, 1998,
to December 31, 1999, who survived and consistently
received hemodialysis for 9 months after the onset
of ESRD. The likelihood of first hospitalization and
death due to cardiac events was assessed during the
follow-up periods. We tested the hypothesis that higher
hematocrit values in the entry period would correlate
with lower morbidity and mortality in the follow-up
period.
As in our previous studies [19–22], we gathered data
on urea reduction ratio (URR) ranges, which are re-
ported on dialysis claims forms (a Medicare reporting re-
quirement) and also adjusted for patients’ demographic
characteristics, clinical characteristics at ESRD onset,
comorbid conditions, and disease severity indicators.
For hospitalization, the follow-up period extended up
to 2 1/2 years from the end of the entry period, with pa-
tients being censored upon a modality change, transplant,
loss-to-follow-up, death, first admission to hospital, or by
December 31, 2000. For mortality, the follow-up period
extended up to 3 years from the end of the entry period,
with patients being censored upon a modality change,
transplant, loss-to-follow-up, death, or by June 30, 2001.
We defined the entry period to be 4 to 9 months after the
first ESRD dialysis service date, plus 90 days. The 90-day
delay was necessary because many patients younger than
65 years of age did not become eligible for Medicare until
90 days after their first dialysis; therefore, the database
might not have been complete during that time.
Patients were excluded from the study if they died,
changed modality to peritoneal dialysis, or had a trans-
plant during the 9 months after their first ESRD dialysis.
When combining patients’ demographic data and base-
line clinical factors, patients with incomplete data (such as
missing birth date, gender, or race, or missing or invalid
values for creatinine level at onset of ESRD) were ex-
cluded. Patients with fewer than four recombinant human
erythropoietin (rHuEPO) claims during the 6-month en-
try period were excluded (38.6% of patients did not have
rHuEPO claims during the entry period) to ensure that
study patients were representative of patients receiving
maintenance therapy for anemia. The average number of
rHuEPO claims during the entry period was 5.53 (stan-
dard deviation, 0.74).
Data sources
Demographic and baseline clinical characteristics at
onset of ESRD, including data on age, gender, race, pri-
mary renal diagnosis, and creatinine level, were obtained
from the Identification and Medical Evidence portions
of the Renal Beneficiary Utilization System (REBUS) of
the Centers for Medicare & Medicaid Services (CMS).
Comorbid conditions were characterized using the Inter-
national Classification of Diseases, Ninth Revision, Clin-
ical Modification (ICD-9-CM) and Physicians’ Current
Procedural Terminology (CPT) codes, as previously de-
scribed [20], from all Medicare Part A and Part B claims
during the 6-month study entry period. Data on disease
severity indicators, such as number of blood transfusions,
vascular access procedures, and hospital days during the
entry period, were extracted from Part A and Part B
Medicare claims files [20]. Hematocrit data were obtained
from Medicare rHuEPO claims files derived from the out-
patient Standard Analytical Files, as previously described
[22]. The URR data for each patient were obtained from
the G-modifier attached to CPT code 90999 with revenue
codes 821 or 825. The baseline URR value for each pa-
tient was the median of the three previous entry period
values [1].
Data on causes of hospitalization were obtained from
the CMS Institutional Inpatient Standard Analytical Files
and classified as ischemic heart disease, cerebrovascular
disease, circulatory system disease, CHF, fluid overload,
cardiomyopathy, or other cardiac disease on the basis of
the principal ICD-9-CM code for each admission. Data
on specific cardiac causes of death (ischemic heart dis-
ease, cerebrovascular disease, circulatory system disease,
CHF, fluid overload, cardiomyopathy, or other cardio-
vascular diseases) were obtained through use of specific
ICD-9-CM codes. Data on all-cause deaths were obtained
from the REBUS Identification and Death Notification
Files.
Statistical analyses
To examine the association between hematocrit value
and first hospitalization due to cardiac disease, separate
Cox regression analyses stratified on the basis of diabetic
status were performed for all-cardiac disease, ischemic
heart disease, cerebrovascular disease, circulatory system
disease, CHF, fluid overload, cardiomyopathy, and other
cardiac diseases. Time to cardiac event was the dependent
variable. To examine the association of hematocrit value
with mortality due to cardiovascular disease, a Cox re-
gression analysis stratified on the basis of diabetic status
was conducted. To compare patient baseline characteris-
tics among the hematocrit groups, the v 2 test was used for
the analysis of categorical variables such as gender, race,
and primary diabetic status, and the Kruskal-Wallis test
was used for the analysis of continuous variables such as
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age, hospital days, and baseline glomerular filtration rate
(GFR).
To assess the pattern of unadjusted first hospitaliza-
tion rates due to cardiac diseases, the association between
hematocrit value and hospitalization was examined and
adjusted for baseline demographic factors (i.e., age, gen-
der, race, and primary renal diagnosis), comorbid con-
ditions, disease severity, GFR, and range of URR. The
relative risks and 95% CI for specific hematocrit groups
were compared to those of patients with hematocrit val-
ues of >33% to ≤36%.
The explanatory predictors were age (<20, 20 to 44,
45 to 64, 65 to 74, and >74 years), race (white, black,
and other), gender, primary diagnosis (diabetes vs. non-
diabetes), comorbid conditions, disease severity, baseline
values of predicted GFR, URR, and hematocrit values.
Comorbid conditions were atherosclerotic heart disease,
CHF, peripheral vascular disease, cerebrovascular acci-
dent or transient ischemic attack, other cardiac diseases,
cancer, chronic obstructive pulmonary disease, gastroin-
testinal disease with bleeding, liver disease, and gall-
bladder disease. For the entry period, disease severity
measures were total inpatient days, with or without blood
transfusions, and with or without vascular access pro-
cedures. The Levey formula [24–26], which takes four
variables (creatinine value, age, gender, and race) into
consideration, was used to calculate the predicted GFR.
Patients were divided into five groups on the basis of the
URR value: <60%, 60% to <65%, 65% to <70%, 70%
to <75%, and ≥75%. Patients also were divided into five
groups on the basis of the hematocrit value: ≤30%, >30%
to ≤33%, >33% to ≤36%, >36% to ≤39%, and >39%.
Monthly hematocrit values less than 10% or greater than




A total of 50,579 incident hemodialysis patients sur-
vived 9 months after their initial dialysis, continued re-
ceiving hemodialysis treatment, and had at least four
rHuEPO claims during the entry period. Of these, 26,207
and 24,372 patients were selected from the 1998 and 1999
cohorts, respectively. Baseline patient characteristics are
summarized in Table 1. As shown in Table 2, when pa-
tients were grouped according to hematocrit value, there
were significant differences (P < 0.0001) in patient char-
acteristics between the >33% to ≤36% group and the
other groups. Also, patients in the groups with higher
hematocrit values (>36% to ≤39% and >39%) were
older and had fewer hospital days and number of vas-
cular access procedures during the entry period. There
were relatively more male and white patients in these
groups as well.
Table 1. Baseline characteristics of 50,579 patients at study entry
Variable unit
Mean age years 65.4 ± 14.3




Diabetes as primary cause of ESRD % 48.1
Mean GFR at ESRD onset mL/min 8.6 ± 3.9
Mean hospital stay days 6.1 ± 11.8
Patients with URR ≥ 70 % 54.3
Mean hematocrit value % 34.1 ± 3.0
Abbreviations are: ESRD, end-stage renal disease; GFR, glomerular filtration
rate; URR, urea reduction ratio.
Unadjusted hospitalization rates due
to cardiac diseases
Unadjusted hospitalization rates (expressed as the
number of the first hospitalizations per 1000 treatment-
years) due to cardiac diseases for nondiabetic, diabetic,
and all patients are provided in Table 3. First hospitaliza-
tion rates due to CHF, fluid overload, cardiomyopathy,
ischemic heart disease, cerebrovascular disease, circula-
tory system disease, and other cardiovascular disease de-
creased as hematocrit values increased, indicating that
hospitalization rates were higher in patients with hemat-
ocrit values of ≤36%, compared to patients with hemat-
ocrit values of >36% to ≤39%.
Adjusted relative risk of hospitalization due
to cardiac diseases
The pattern of unadjusted first hospitalization rates
due to cardiac diseases may reflect differences be-
tween groups in baseline characteristics or the presence
of comorbid conditions; therefore, additional analyses
were conducted after adjustment of demographic factors.
Table 4 presents the relative risks of hospitalization due to
cardiac disease according to controlled variables. All the
relative risks and 95% CI for specific hematocrit groups
were compared to those of the >33% to ≤36% hemat-
ocrit group.
Using follow-up data, we compared patients with
hematocrit values of >36% to ≤39% and those with
values of >39% to patients with hematocrit values of
>33% to ≤36%. On the basis of hospitalization rate
due to any cardiac cause, patients with hematocrit val-
ues of >36% to ≤39% and those with values of >39%
had risk ratios of 0.92 (95% CI 0.88 to 0.97) and 0.79
(95% CI 0.72 to 0.87), respectively (Fig. 1). On the basis
of first hospitalization due to CHF, fluid overload, or car-
diomyopathy, patients with hematocrit values of >36%
to ≤39% and those with values of >39% had risk ratios
of 0.85 (95% CI 0.77 to 0.95) and 0.80 (95% CI 0.65 to
0.97), respectively (Fig. 2). On the basis of first hospi-
talization due to ischemic heart disease, cerebrovascular
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Table 2. Baseline patient characteristics according to hematocrit value
Hematocrit value %
Variable unit ≤30 >30 to ≤33 >33 to ≤36 >36 to ≤39 >39 P
Patients number 4308 11,558 22,192 10,265 2256
Mean age years 61.3 ± 15.5 64.6 ± 14.4 66.1 ± 13.9 66.2 ± 14.1 66.1 ± 14.2 <0.0001a
Male % 48.3 48.0 50.8 53.1 54.8 <0.0001b
Race %
White 51.6 59.9 63.1 62.1 59.2 <0.0001b
Black 44.2 34.8 30.7 31.1 34.1 <0.0001b
Diabetes as primary cause of ESRD % 45.4 50.6 48.4 46.4 46.3 <0.0001b
Mean GFR at ESRD onset mL/min 8.4 ± 4.0 8.6 ± 3.9 8.6 ± 3.9 8.7 ± 4.0 8.6 ± 4.1 <0.0001a
Mean hospital stay days 13.0 ± 17.6 8.6 ± 13.8 4.9 ± 9.9 3.7 ± 8.7 4.0 ± 9.7 <0.0001a
Mean NVP 3.9 ± 5.8 3.4 ± 5.6 2.6 ± 8.3 2.3 ± 4.5 2.4 ± 5.3 <0.0001a
Mean hematocrit % 28.0 ± 2.0 31.8 ± 0.8 34.5 ± 0.8 37.2 ± 0.8 40.6 ± 1.5 <0.0001a
Abbreviations are: ESRD, end-stage renal disease; GFR, glomerular filtration rate; NVP, number of vascular access procedures.
aKruskal-Wallis test; b v 2 test.
Table 3. Unadjusted hospitalization ratesa due to cardiac diseases
according to hematocrit value
Hematocrit value %
≤30 >30 to ≤33 >33 to ≤36 >36 to ≤39 >39
Nondiabetic patients
All cardiac 521 401 344 297 251
CHFb 182 107 88 72 63
Ischemicc 175 168 148 132 117
Otherd 165 125 108 93 72
Diabetic patients
All cardiac 507 463 379 340 301
CHFb 162 134 93 73 73
Ischemicc 242 238 213 191 165
Otherd 103 91 72 75 62
All patients
All cardiac 515 430 360e 316e 273e
CHFb 173 120 90 73 67
Ischemicc 204 201 177 158 137
Otherd 138 109 92 86 68
CHF is congestive heart failure.
aExpressed as number of first hospitalizations per 1000 treatment-years; bCHF,
fluid overload, and cardiomyopathy; cIschemic heart disease, cerebrovascular
disease, and circulatory system disease; dAll other cardiovascular disease; eSum
is result after rounding.
disease, or circulatory system disease, patients with hema-
tocrit values of >36% to ≤39% and those with values
of >39% had risk ratios of 0.94 (95% CI 0.88 to 1.01)
and 0.81 (95% CI 0.70 to 0.93), respectively (Fig. 2).
For first hospitalization due to all other cardiac causes,
patients with hematocrit values of >36% to ≤39% and
those with values of >39% had risk ratios of 0.95 (95% CI
0.87 to 1.05) and 0.76 (95% CI 0.62 to 0.92), respectively
(Fig. 2).
Adjusted relative risk of hospitalization for patients
with cardiac comorbid conditions
To determine the association between hospitalization
and hematocrit values for hemodialysis patients with car-
diac diseases, we investigated a subgroup (N = 45,166) of
patients with one or more of the following comorbid con-
ditions: atherosclerotic heart disease, CHF, peripheral
vascular disease, cerebrovascular accident or transient
ischemic attack, and other cardiac diseases. We found a
pattern similar to that of the relationship between hospi-
talization and hematocrit value in all selected hemodial-
ysis patients; patients with higher hematocrit values had
fewer hospitalizations. Compared to patients with hema-
tocrit values of >33% to ≤36% on the basis of first
hospitalization due to any cardiac cause, patients with
hematocrit values of >36% to ≤39% and those with val-
ues of >39% had risk ratios of 0.93 (95% CI 0.89 to 0.98)
and 0.79 (95% CI 0.71 to 0.87), respectively, in the follow-
up period (Fig. 3).
Adjusted relative risk of death due to cardiac
diseases and all-cause death
Table 4 presents the relative risks of death due to car-
diac disease according to controlled variables. The ad-
justed relative risks of death due to any cardiac cause are
shown in Figure 4. As previously indicated, the possible
duration of follow-up for mortality extended to 3 years.
Higher hematocrit values were associated with lower
likelihood of death in the follow-up period. Compared
to patients with hematocrit values of >33% to ≤36%,
patients with hematocrit values of >36% to ≤39% and
those with values of >39% had risk ratios of 0.92 (95% CI
0.87 to 0.98) and 0.83 (95% CI 0.74 to 0.93), respectively,
in the follow-up period.
As shown in Figure 5, the same pattern was observed
for all-cause deaths (i.e., deaths from cardiac disease, in-
fection, and other causes). Compared to patients with
hematocrit values of >33% to ≤36%, patients with hema-
tocrit values of >36% to ≤39% and those with values of
>39% had risk ratios of 0.92 (95% CI 0.88 to 0.96) and
0.86 (95% CI 0.80 to 0.93), respectively, in the follow-up
period.
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Table 4. Relative risks of cardiac hospitalization and cardiac death according to controlled variables
Hospitalization due to cardiac disease Death due to cardiac disease
Variable RR Lower limit Upper limit RR Lower limit Upper limit
Age <20 years 1.59 1.07 2.37 0.43 0.11 1.72
Age 20–44 years (reference) 1.00 1.00
Age 45–64 years 1.00 0.93 1.08 1.58 1.40 1.77
Age 65–74 years 0.88 0.81 0.95 1.95 1.73 2.19
Age >74 years 0.91 0.84 0.99 2.87 2.55 3.24
Female gender (reference) 1.00 1.00
Male gender 0.95 0.91 0.99 1.05 1.00 1.10
White race (reference) 1.00 1.00
Black race 0.93 0.89 0.97 0.72 0.69 0.76
Other race 0.78 0.72 0.85 0.93 0.85 1.02
ASHD 1.39 1.33 1.46 1.23 1.16 1.29
CHF 1.23 1.17 1.29 1.45 1.36 1.54
Other cardiac disease 1.13 1.08 1.19 1.23 1.15 1.31
Peripheral vascular disease 1.09 1.04 1.13 1.10 1.04 1.15
CVA/TIA 1.12 1.07 1.16 1.08 1.03 1.12
Cancer 0.96 0.92 1.01 0.97 0.93 1.02
Gallbladder disease 0.92 0.87 0.99 0.98 0.92 1.05
COPD 1.13 1.09 1.18 1.20 1.15 1.26
Gastrointestinal disease with bleeding 1.04 0.99 1.08 1.08 1.03 1.13
Liver disease 1.00 0.96 1.04 0.99 0.95 1.04
No hospitalization (reference) 1.00 1.00
Hospitalized 1–10 days 1.44 1.38 1.51 1.19 1.13 1.25
Hospitalized 11–20 days 1.80 1.69 1.93 1.58 1.48 1.70
Hospitalized >20 days 1.85 1.72 1.99 1.78 1.65 1.91
No blood transfusion (reference) 1.00 1.00
Blood transfusion 0.97 0.89 1.06 1.10 1.01 1.20
No vascular access (reference) 1.00 1.00
Vascular access 0.90 0.87 0.94 0.94 0.90 0.98
GFR (continuous variable) 1.01 1.00 1.01 1.04 1.03 1.04
URR <60% 1.08 1.01 1.15 1.11 1.03 1.19
URR 60% to <65% 1.01 0.94 1.08 1.03 0.96 1.11
URR 65% to <70% (reference) 1.00 1.00
URR 70% to <75% 0.99 0.94 1.05 0.94 0.88 0.99
URR ≥75% 0.96 0.91 1.01 0.93 0.88 0.99
Abbreviations are: ASHD, arteriosclerotic heart disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CVA/TIA, cerebrovascular
















10–30 >30–33 >33–36  >36–39 >39
Hematocrit, %
1.18 1.07 1.00 0.92 0.79
Fig. 1. Adjusted relative risk of first hospitalization due to any cardiac
cause, according to hematocrit value. Data are expressed as relative risk
and 95% CI.
Adjusted relative risks of hospitalization and death for
patients without preexisting cardiac disease
Results for patients without preexisting cardiac disease
showed that patients with hematocrit values of >36%
to ≤39% had lower adjusted risks of hospitalization and
death during the follow-up period, as compared to pa-
tients with hematocrit values of >33% to ≤36%. Their


















10–30 >30–33 >33–36 >36–39 >39
Hematocrit, %
Fig. 2. Adjusted relative risk of first hospitalization due to particular
cardiac causes, according to hematocrit value. Data are expressed as
relative risk and 95% CI. Symbols are: ( ) patients with congestive heart
failure, fluid overload, or cardiomyopathy; () patients with ischemic
heart disease, cerebrovascular disease, or circulatory system disease; ( )
patients with other cardiac diseases.
0.78 (P < 0.0001), 0.74 (P = 0.0005), 0.71 (P = 0.026), 0.68
(P = 0.045), and 0.79 (P = 0.07) for all-cause death; any
cardiac death; all-cause hospitalization; any cardiac hos-
pitalization; hospitalization due to ischemic heart disease
and cerebrovascular disease; hospitalization due to CHF,





















Fig. 3. Adjusted relative risk of first hospitalization due to any car-
diac cause for patients with cardiac comorbid conditions, according to

















10–30 >30–33 >33–36 >36–39 >39
Hematocrit, %
1.39
1.14 1.00 0.92 0.83
Fig. 4. Adjusted relative risk of death due to any cardiac cause, accord-
























Fig. 5. Adjusted relative risks of death due to any cause, according to
hematocrit value. Data are expressed as relative risk and 95% CI.
fluid overload, and cardiomyopathy; and hospitalization
due to other cardiac disease, respectively.
We also performed analyses using a 3-month entry pe-
riod after 90 days of ESRD, with follow-up periods of 1,
2, and 3 months. We obtained similar results (data not
shown).
In addition, we analyzed on the basis of broader en-
rollment criteria, increasing the sample size from 50,579
patients with four or more rHuEPO claims to 52,026 pa-
tients with three or more rHuEPO claims, and to 52,473
patients with two or more rHuEPO claims. Again, we
obtained similar results (data not shown).
DISCUSSION
In this study of incident hemodialysis patients, we
found that patients with hematocrit values in the 6-month
entry period of >36% to ≤39% and >39% were at signifi-
cantly lower risk of hospitalization and death (cardiac and
all-cause) in follow-up periods of 21/2 years and 3 years,
respectively. These findings are consistent with and build
on the findings of a previous study by our group, in which
we found hematocrit values of >36% to ≤39% to be as-
sociated with positive effects on morbidity and mortality
[22]. We also found that results were similar for both pa-
tients with and those without preexisting cardiac disease,
that is, higher hematocrit values were associated with re-
duced morbidity and mortality in the follow-up period.
We hypothesize that patients without established cardiac
disease may receive a significant benefit from anemia cor-
rection, compared to patients with established cardiac
disease.
Previous investigations of hematocrit values and asso-
ciated outcomes in nondialysis populations have yielded
contradictory results. In patients with cardiac disease,
studies have linked a high hematocrit value (≥33%) to
myocardial infarction [5], a reduction in the cardiac index
[6], and coronary heart disease [7]. Other studies of pa-
tients with cardiac disease have linked a low hematocrit
value to an increased mortality due to coronary artery
disease [8], an increased prevalence of traditional cardio-
vascular risk factors [9], and poor clinical course after
acute myocardial infarction [10].
Similarly, studies of hematocrit values in ESRD pa-
tients have produced conflicting findings. Anemia has
been linked to CHF and left ventricular hypertrophy
[11], its partial correction seems to have improved car-
diac performance and induced regression of left ventric-
ular hypertrophy in 11 patients, and full correction (to
a hematocrit value of 40%) was found more effective
than partial correction in nine predialysis patients with
chronic renal failure who were receiving rHuEPO ther-
apy [13]. A prospective study of hemodialysis patients
with no cardiovascular disease suggested that normaliza-
tion of hematocrit values improved quality of life and de-
creased morbidity [14]. Some randomized clinical studies
in hemodialysis patients with cardiac disease found that
normalization of the hematocrit value did not cause in-
creased blood pressure or change the level of silent is-
chemia; morbidity and mortality outcomes were unclear
[16–18]. A clinical trial in hemodialysis patients without
symptomatic heart disease found no difference in left ven-
tricular mass index between patients whose hematocrit
value had been normalized and those whose anemia had
been only partially corrected [27].
We believe our results to be important for several rea-
sons. Because the study was conducted in a nationwide
sample of patients, its findings do not reflect local prac-
tices. Previous studies have analyzed data from smaller
numbers of patients. We analyzed data from a very large
number of patients; this allowed us to analyze, for ex-
ample, patients with hematocrit values of >39% as an
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independent group. Earlier studies analyzed data from
an earlier time, when there was less consistency in care.
Because of the relative newness of our data (data from
January 1, 1998, through December 31, 1999), our find-
ings reflect care given under NKF DOQI guidelines. Our
finding of a greater number of patients with hematocrit
values of >39% may reflect more active care being given
in the current era to correct anemia in ESRD patients.
Finally, by including GFR and URR data in our analyses,
we ensured that our findings reflect a greater complex-
ity of disease than that previously studied. Our results
are consistent with those of Silverberg et al [28], who
studied patients with CHF to determine the prevalence
and severity of anemia and the effects of its correction
on cardiac function, renal function, and hospitalization.
The investigators found successful treatment of anemia
to be associated with a significant improvement in cardiac
function and renal function and as well as a marked de-
crease in the need for diuretics and hospitalization in pa-
tients not on dialysis. Our results are also consistent with
findings in two studies of patients with chronic anemia,
which showed the beneficial effect of blood transfusion
on ejection fraction and cardiac function in nondialysis
patients [29, 30]. Such results are supported by a study in
rats, in which a direct relationship was found between
anemia and cardiac disease, especially cardiomegaly
[31].
Explanations can be offered regarding the observed
relationship between lower hematocrit values and poor
clinical outcome. The association in hemodialysis patients
of inflammation with lower hematocrit values and higher
morbidity and mortality [32, 33] may help explain our
finding of an association between hematocrit value and
outcome. Lower hematocrit values and poor outcomes
may also be secondary to dilution in high weight gain-
ers. Due to data limitations, we could not test these
associations.
However, when evaluating clinical outcomes, one
should be cautious with regard to patients with hemat-
ocrit values of >39%. It may be argued that patients with
hematocrit values of >39% were healthier compared to
patients with lower hematocrit values. In our study, com-
pared to patients with hematocrit values of ≤33%, those
with hematocrit values of >39% were older (mean age
66.1 vs. 63.7 years), used less rHuEPO in the entry period
(mean doses/month 49,726 vs. 78,362), and were less likely
to have preexisting cardiac disease (86.8% vs. 91.2%). We
also investigated whether polycystic kidney disease was
present to a greater extent in patients with higher hemat-
ocrit values. Diabetes, hypertension, glomerulonephritis,
and cystic kidney disease accounted for 48.7%, 28.9%,
7.5%, and 1.4%, respectively, of patients with hemat-
ocrit values of ≤36%, and for 46.4%, 31.2%, 7.9%, and
2.3%, respectively, of patients with hematocrit values of
>36%.
In the United States, achieving higher hematocrit val-
ues has been associated with large expenditures for
rHuEPO, approaching $1.5 billion per year [34]. Com-
pared to patients with higher hematocrit values, patients
with lower hematocrit values use more than twice the
amount of rHuEPO [22], which appears to be driving the
high cost. rHuEPO resistance in the United States ap-
pears to be secondary to dialysis catheter utilization [35]
as well as increased comorbidity and severity of disease,
as shown in our study (Table 2). These findings suggest
that if higher hematocrit values are of any benefit, more
cost-effective use of rHuEPO is needed. A detailed inves-
tigation of factors associated with lower hematocrit val-
ues and higher rHuEPO doses was beyond the scope of
this study but should be undertaken. Prospective clinical
trials should be undertaken to investigate the associa-
tions found in our study. If such trials confirm the associ-
ations we found, it is likely that target hematocrit values
will be raised and possible that cost of rHuEPO therapy
will increase. However, total cost of care should also be
considered.
The chief limitation of our work is that, being an ob-
servational study, it can establish an association but not
a causal relationship between higher hematocrit values
and lower risks of cardiovascular morbidity and mor-
tality. Also, the national data do not include values for
pre- and postdialysis weight (allowing calculation of the
interdialytic weight gain) and cannot allow determination
of the relationships of inflammatory markers to hemat-
ocrit values and outcomes in hemodialysis patients. Other
limitations include possible selection bias (only patients
with more than four rHuEPO/hematocrit claims were in-
cluded). In addition, hospitalization and mortality are just
two of many important measures of outcome and quality
of life in ESRD patients. Studies of long-term outcomes
and quality of life based on a large ESRD population are
needed.
CONCLUSION
We found higher hematocrit values to be associated
with lower hospitalization and mortality (cardiac and all-
cause) in incident hemodialysis patients, even in those
with cardiac disease. These findings are based on 1998 to
1999 data and therefore reflect current clinical practice
under NKF DOQI guidelines. For the 2- to 3-year pe-
riod following initiation of hemodialysis, there appears
to be diminished risk of hospitalization and death for
patients whose hematocrit values are maintained in the
>36% to ≤39% range during the entry period. The sig-
nificant associations we report do not establish a causal
relationship between higher hematocrit values and lower
risks of cardiac morbidity and mortality. A randomized
clinical trial in low-risk patients is needed to establish
causality.
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